J
Joseph Paul Eder
Researcher at Yale University
Publications - 197
Citations - 20877
Joseph Paul Eder is an academic researcher from Yale University. The author has contributed to research in topics: Cancer & Pharmacokinetics. The author has an hindex of 52, co-authored 187 publications receiving 17628 citations. Previous affiliations of Joseph Paul Eder include Beth Israel Deaconess Medical Center & Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
Pembrolizumab for the treatment of non-small cell lung cancer
Edward B. Garon,Naiyer A. Rizvi,Rina Hui,Natasha B. Leighl,Ani Sarkis Balmanoukian,Joseph Paul Eder,Amita Patnaik,Charu Aggarwal,Matthew A. Gubens,Leora Horn,Enric Carcereny,Myung-Ju Ahn,Enriqueta Felip,Jong-Seok Lee,Matthew D. Hellmann,Omid Hamid,Jonathan W. Goldman,Jean-Charles Soria,Marisa Dolled-Filhart,Ruth Z. Rutledge,Jin Zhang,Jared Lunceford,Reshma A. Rangwala,Gregory M. Lubiniecki,Charlotte Roach,Kenneth Emancipator,Leena Gandhi +26 more
TL;DR: Pembrolizumab had an acceptable side-effect profile and showed antitumor activity in patients with advanced non-small-cell lung cancer and PD-L1 expression in at least 50% of tumor cells correlated with improved efficacy of pembrolIZumab.
Journal ArticleDOI
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Thomas Powles,Joseph Paul Eder,Gregg Fine,Fadi Braiteh,Yohann Loriot,Cristina Cruz,Joaquim Bellmunt,Howard A. Burris,Daniel P. Petrylak,Siew-leng Melinda Teng,Xiaodong Shen,Zachary Boyd,Priti S. Hegde,Daniel S. Chen,Nicholas J. Vogelzang +14 more
TL;DR: It is demonstrated that tumours expressing PD-L1-positive tumour-infiltrating immune cells had particularly high response rates, and patients with UBC, who are often older and have a higher incidence of renal impairment, may be better able to tolerate MPDL3280A versus chemotherapy.
Journal ArticleDOI
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
Tanguy Y. Seiwert,Barbara Burtness,Ranee Mehra,Jared Weiss,Raanan Berger,Joseph Paul Eder,Karl Heath,Terrill K. McClanahan,Jared Lunceford,Christine K. Gause,Jonathan D. Cheng,Laura Qm Chow +11 more
TL;DR: Pembrolizumab was well tolerated and demonstrated clinically meaningful antitumour activity in recurrent or metastatic squamous cell carcinoma of the head and neck, supporting further study of pembrolIZumab as anticancer therapy for advancedHead and neck cancers.
Journal ArticleDOI
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
Scott J. Antonia,Jose A. Lopez-Martin,Johanna C. Bendell,Patrick A. Ott,Matthew H. Taylor,Joseph Paul Eder,Dirk Jäger,M. Catherine Pietanza,Dung T. Le,Filippo de Braud,Michael A. Morse,Paolo A. Ascierto,Leora Horn,Asim Amin,Rathi N. Pillai,Jeffry Evans,Ian Chau,Petri Bono,Akin Atmaca,Padmanee Sharma,Christopher T. Harbison,Chen Sheng Lin,Olaf Christensen,Emiliano Calvo +23 more
TL;DR: An objective response was achieved in ten (10%) of 98 patients receiving nivolumab 3 mg/kg, one (33%) of three patients receivingnivolUMab 1mg/kg plus ipilimumab 1 mg /kg, and 14 (23%) of 61 receiving n ivolumAB 1 mg/ kg plus ipILimumab 3mg/ kg, and ten (19%) of 54 receiving nvolum ab 3 mg / kg plusipilimum
Journal ArticleDOI
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
Kei Muro,Hyun Cheol Chung,Veena Shankaran,Ravit Geva,Daniel V.T. Catenacci,Shilpa Gupta,Joseph Paul Eder,Talia Golan,Dung T. Le,Barbara Burtness,Autumn J. McRee,Chia-Chi Lin,Kumudu Pathiraja,Jared Lunceford,Kenneth Emancipator,Jonathan Juco,Minori Koshiji,Yung-Jue Bang +17 more
TL;DR: In this population of patients with recurrent or metastatic PD-L1-positive gastric cancer, pembrolizumab had a manageable toxicity profile and promising antitumour activity, warranting further study in phase 2 and 3 trials.